Disclosure Information: Research and development expense
   
Label: Research and development expense
Name: ResearchAndDevelopmentExpense
Type: Disclosure
Parent Topic: OtherFinancialStatementAccounts
Documentation: The disclosure of research and development expense. [Refer: Research and development expense]
Commentary:
Text Block Name: ifrs-full:DisclosureOfResearchAndDevelopmentExpenseExplanatory
SEC Level: Disclosure
Concept arrangement pattern: [Hierarchy]
Completion state:
Status: OK
Standards: IAS-10- e-
Exemplars: 16 examples
Taxonomy Network:
Prototype for disclosure: Machine Readable
Line Label Object Class (Data type) Period Type Balance Report Element Name
Business Rules for Disclosure: Controlled Natural Language 
Rules for disclosure: ResearchAndDevelopmentExpense 
This disclosure:

   - MUST be represented as an SEC 'Level' (i.e. Document, Statement, Disclosure, Schedule) type: Disclosure
Business Rules for Disclosure: Machine-Readable
From Arcrole (predicate) To
ResearchAndDevelopmentExpense disclosure-isSECType Disclosure
Exemplars for Disclosure: Machine-Readable
Entity Name and Text Block or Detailed Disclosure
AC Immune SA | Affimed N.V. | Auris Medical Holding AG | Biofrontera AG | BiondVax Pharmaceuticals Ltd. | CELYAD S.A. | CGG | DBV Technologies S.A. | Eviation Aircraft Ltd. | InflaRx N.V. | KOREA ELECTRIC POWER CORP | MAZOR ROBOTICS LTD. | POSCO | TiGenix NV | TIM S.p.A. | XTL BIOPHARMACEUTICALS LTD |

*

Creative Commons License
This work is licensed under a Creative Commons License.

Last updated: 12/20/2019 6:50:05 PM